Orally delivered all-trans-retinoic acid- and transforming growth factor-β-loaded microparticles ameliorate type 1 diabetes in mice-Reference-Cited by-同舟云学术

Orally delivered all-trans-retinoic acid- and transforming growth factor-β-loaded microparticles ameliorate type 1 diabetes in mice

Published:2019-12 Issue: Volume:864 Page:172721
ISSN:0014-2999
Container-title:European Journal of Pharmacology
language:en
Short-container-title:European Journal of Pharmacology

Author:

Koprivica Ivan,Gajic Dragica,Saksida Tamara,Cavalli Eugenio,Auci Dominick,Despotovic Sanja,Pejnovic Nada,Stosic-Grujicic Stanislava,Nicoletti Ferdinando,Stojanovic Ivana

Funder

Ministry of Education, Science and Technological Development, Republic of Serbia

Publisher

Elsevier BV

Subject

Pharmacology

Reference44 articles.

1. Gelatinases (MMP-2 and MMP-9) are preferentially expressed by Th1 vs. Th2 cells;Abraham;J. Neuroimmunol.,2005

2. Type 1 diabetes;Atkinson;Lancet,2014

3. Anti-fibrotic potential of all trans retinoic acid in inflammatory bowel disease;Auci;Gastroenterol. Pancreatol. Liver Disord.,2018

4. All-trans retinoic acid mediates enhanced Treg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation;Benson;J. Exp. Med.,2007

5. T cell-mediated beta cell destruction: autoimmunity and alloimmunity in the context of type 1 diabetes;Burrack;Front. Endocrinol. (Lausanne),2017

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mesenchymal Stem Cells from Mouse Hair Follicles Inhibit the Development of Type 1 Diabetes;International Journal of Molecular Sciences;2024-05-29

2. Improving oral absorption of tretinoin by ionic liquids technology;Journal of Drug Delivery Science and Technology;2024-05

3. Development of Type 1 Diabetes in Mice Is Associated with a Decrease in IL-2-Producing ILC3 and FoxP3+ Treg in the Small Intestine;Molecules;2023-04-11

4. Particle-Based therapies for antigen specific treatment of type 1 diabetes;International Journal of Pharmaceutics;2023-01

5. Leverage biomaterials to modulate immunity for type 1 diabetes;Frontiers in Immunology;2022-11-02